Stablizing An Enzyme By Forming A Mixture, An Adduct Or A Composition, Or Formation Of An Adduct Or Enzyme Conjugate Patents (Class 435/188)
  • Patent number: 10724103
    Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: July 28, 2020
    Inventors: Ozlem Tureci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schluter, Dirk Usener, Philippe Thiel, Michael Koslowski
  • Patent number: 10723789
    Abstract: The present invention is concerned with immunoglobulin (Ig)-like molecules or fragments thereof for use in treatment, prevention, or prevention of progression of adverse cardiac remodelling and conditions resulting from or relating to myocardial infarction and pressure-overload, such as heart failure, aneurysm formation and remote myocardial fibrosis and for use in improving angiogenesis, preferably after ischemic injury. The invention also provides nucleic acid molecules encoding said Ig-like molecules, vectors comprising same, and host cells comprising same.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 28, 2020
    Assignee: UMC UTRECHT HOLDING B.V.
    Inventor: Fatih Arslan
  • Patent number: 10624966
    Abstract: The present invention is directed to compositions comprising a polymer backbone with protective chain and anionic groups, and a cationic therapeutic agent. The present invention is directed to compositions for treating infections, inflammatory diseases, excess growth, and damaged cells and organs.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: April 21, 2020
    Assignee: PharmaIN Corporation
    Inventors: Gerardo M. Castillo, Elijah M. Bolotin, Akiko Nashimoto-Ashfield
  • Patent number: 10626165
    Abstract: Fibronectin type III domains (FN3) that specifically bind to CD8A, related polynucleotides capable of encoding CD8A-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, and detectably labeled FN3 domains are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: April 21, 2020
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 10624954
    Abstract: There are disclosed compositions and methods for treating obesity using 5-D-fructose dehydrogenase. Other embodiments are also described.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: April 21, 2020
    Assignee: PRO NATURA GESELLSCHAFT FÜR GESUNDE ERNÄHRUNG GMBH
    Inventors: Daniel Henry Wyrobnik, Isaac Harry Wyrobnik
  • Patent number: 10618941
    Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: April 14, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
  • Patent number: 10596232
    Abstract: Disclosed herein are methods and compositions related to coagulation factor complexes comprising a coagulation factor; a fusion protein; and a modifying molecule, wherein the modifying molecule is coupled to the coagulation factor in such a way as to allow binding by the fusion protein, thereby creating a modified coagulation factor; wherein the modified coagulation factor and the fusion protein interact in at least two independent sites.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: March 24, 2020
    Assignee: Cell Machines, Inc.
    Inventor: James Kelly
  • Patent number: 10577637
    Abstract: An enzyme electrode includes an electrode, and a detection layer which contacts the electrode and contains a crosslinking agent, an electrically conductive macromolecule and an enzyme transferring and receiving electrons to and from the electrode and does not contain an electron transfer subunit.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 3, 2020
    Assignees: ARKRAY, Inc., Ultizyme International Ltd.
    Inventors: Koji Katsuki, Hisashi Kaneda, Junko Shimazaki
  • Patent number: 10564162
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 18, 2020
    Assignee: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • Patent number: 10527618
    Abstract: Means for enabling an immunoassay with a sufficient sensitivity in an immunoassay for measuring influenza virus in a sample using influenza virus M1 protein as an antigen is provided. A sample processing method in an immunoassay for influenza virus, which method comprises, in an immunoassay for influenza virus using an antibody which undergoes antigen-antibody reaction with influenza virus matrix 1 protein, or an antigen-binding fragment thereof, bringing a sample containing influenza virus into contact with a sample processing liquid containing a surfactant having at least one group selected from the group consisting of palmityl, stearyl, and oleyl, is provided.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: January 7, 2020
    Assignee: DENKA SEIKEN CO., LTD.
    Inventors: Yuki Shinohara, Takashi Miyazawa
  • Patent number: 10526590
    Abstract: The present invention relates to guide RNAs comprising adaptor segments having one or more modifications, and their use in homologous recombination by CRISPR:Cas systems. The modified adaptor segments are resistant to degradation by RNaseH. The present invention also relates to a dual guide RNA strategy in which a first guide RNA directs a Cas enzyme to make a double-strand break at a first target sequence, and a second guide RNA comprises an adaptor segment attached to a donor polynucleotide, and binds a second target sequence that is offset from the first target sequence.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: January 7, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Andrew Kennedy, Gusti Zeiner, Subhadeep Roy, Chong Wing Yung
  • Patent number: 10392611
    Abstract: Disclosed herein are compositions and methods for reducing the antigenicity of molecules, wherein the molecule comprises a uricase. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 27, 2019
    Assignee: Duke University
    Inventors: Ashutosh Chilkoti, Yizhi Qi, Michael S. Hershfield, Nancy J. Ganson
  • Patent number: 10386367
    Abstract: A method for producing an examination reagent includes adding a helper ligand to an unfolded receptor protein in an initial solution so as to provide a pre-solution of the examination reagent with a folded receptor protein. The folded receptor protein comprises a bonded helper ligand which can be exchanged with an examination peptide.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: August 20, 2019
    Assignee: JACOBS UNIVERSITY BREMEN GGMBH
    Inventors: Sebastian Hartmut Springer, Sunil Kumar Saini
  • Patent number: 10378050
    Abstract: This disclosure relates to the use of one or more proteins (e.g., globular proteins) having a low isoelectric point and/or a limited number (e.g., zero) of modifying groups in nucleic acid polymerization and/or amplification reactions such as polymerase chain reaction (PCR).
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: August 13, 2019
    Assignee: Life Technologies Corporation
    Inventors: Jonathan Wang, David Dupont
  • Patent number: 10364451
    Abstract: Disclosed herein are compositions and methods for reducing the antigenicity of molecules. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 30, 2019
    Assignee: Duke University
    Inventors: Ashutosh Chilkoti, Yizhi Qi, Michael S. Hershfield, Nancy J. Ganson
  • Patent number: 10352928
    Abstract: The present disclosure provides target detection and quantification systems as well as related methods based on the use of steric hindrance (either created by the target itself or a macromolecular entity used to bind to the target) to prevent or limit the hybridizing between an anchoring oligonucleotide (associated to a substrate) and a signaling oligonucleotide or a combination of signaling oligonucleotides (capable of specifically binding the target or the macromolecular entity).
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: July 16, 2019
    Inventors: Alexis Vallée-Bélisle, Sahar Sadat Mahshid
  • Patent number: 10329602
    Abstract: This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundres of megabases in length.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: June 25, 2019
    Assignee: Alere San Diego, Inc.
    Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
  • Patent number: 10254298
    Abstract: The various technologies presented herein relate to identifying whether an individual has taken, and/or is under the influence of, a restricted drug. A density separation technique is utilized, wherein a sample (e.g., blood, saliva, urine, etc.,) which may include an analyte is exposed to a first plurality of beads having an analyte attached thereto, a second plurality of beads having a metabolite-specific antibody attached thereto, and a plurality of fluorophore-labelled analyte-specific antibodies. After incubation, any analyte in the sample (e.g., delta-9-THC) is bound to the fluorophore-labelled analyte-specific antibodies, any free fluorophore-labelled analyte-specific antibodies are attached to the analyte of the first beads, and any metabolite in the sample is bound to the second antibody. By applying centrifugal separation, the first beads move to a region which undergoes irradiation.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: April 9, 2019
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventor: Chung-Yan Koh
  • Patent number: 10160958
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: December 25, 2018
    Assignee: Horizon Pharma Rheumatology LLC
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Patent number: 10150945
    Abstract: A low-cost cell culture device with low cytotoxicity and improved cell adhesion is described, manufactured by a simplified coating process. At least the portion for cell culture on the surface of the cell culture device is coated with at least one of ?-poly-L-lysine, further polymerized derivatives of ?-poly-L-lysine and their salts.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: December 11, 2018
    Assignees: JNC CORPORATION, TAKESHI NAGASAKI
    Inventors: Takeshi Nagasaki, Seiji Shinkai, Atsushi Uno
  • Patent number: 10138470
    Abstract: The object is to provide a novel enzyme exhibiting cholesterol dehydrogenase activity. Provided is a mutant enzyme having an amino acid sequence of a microorganism-derived cholesterol oxidase, which is composed of: (1) an amino acid corresponding to the amino acid at the position 113 of the amino acid sequence of SEQ ID NO: 1; (2) an amino acid corresponding to the amino acid at the position 362 of the amino acid sequence of SEQ ID NO: 1; (3) an amino acid corresponding to the amino acid at the position 402 of the amino acid sequence of SEQ ID NO: 1; (4) an amino acid corresponding to the amino acid at the position 412 of the amino acid sequence of SEQ ID NO: 1; (5) an amino acid corresponding to the amino acid at the position 468 of the amino acid sequence of SEQ ID NO: 1; and others.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: November 27, 2018
    Assignee: AMANO ENZYME INC.
    Inventors: Kazunori Yoshida, Kyoichi Nishio
  • Patent number: 10052379
    Abstract: The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.
    Type: Grant
    Filed: July 3, 2017
    Date of Patent: August 21, 2018
    Assignee: ALERE SAN DIEGO, INC.
    Inventors: Mariusz Banaszczyk, Normand Hébert, Neil Stowe
  • Patent number: 10047352
    Abstract: Methods for producing intein-modified proteases are provided. Expression cassettes and vectors for using to genetically engineer hosts are described. Hosts genetically engineered to express one or more intein-modified proteases using expression cassettes and vectors of the invention are also provided. Methods to produce a protease and regulate its activity are described.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: August 14, 2018
    Assignee: AGRIVIDA, INC.
    Inventors: R. Michael Raab, Binzhang Shen, Gabor Lazar, Humberto De La Vega
  • Patent number: 10030264
    Abstract: Methods for performing analytical reactions and compositions for use in such methods, where the methods have reduced signal levels deriving from non-specific adsorption of detected reagents to other components of the analytical method, e.g., other reagents, solid phase components, vessels, etc.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: July 24, 2018
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Andrei Fedorov, Stephen Yue, Lei Sun, Gene Shen, John Lyle
  • Patent number: 10029021
    Abstract: As a substance used as a contrast agent for a method of nuclear magnetic resonance analysis or a method of magnetic resonance imaging, a substance with high selectivity and high sensitivity was demanded. According to the present invention, when a polymer having, in a side chain thereof, a sequence of a 1H—13C—15N, 1H—15N—13C or 1H—13C—13C bond, that is, a structure labeled with stable isotopes of 13C and 15N, is used, the abundance of such a sequence in one molecule can be increased, and hence, high selectivity and higher sensitivity can be attained when used as a contrast agent.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: July 24, 2018
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Teruyuki Kondo, Yasuhiro Aoyama, Hisatsugu Yamada, Yoshinori Hasegawa, Hidehito Tochio, Yu Kimura, Masahiro Shirakawa, Fuminori Sugihara, Tetsuya Matsuda, Shinsuke Sando, Masato Minami, Fumio Yamauchi, Tetsuya Yano, Hidetoshi Tsuzuki
  • Patent number: 10000815
    Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: June 19, 2018
    Assignees: THE GENERAL HOSPITAL CORPORATION, DANA-FARBER CANCER INSTITUTE, INC
    Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
  • Patent number: 9937239
    Abstract: A method of preserving a cell-free protein expression system includes preserving a cell extract with a first non-reducing sugar alcohol to provide a preserved cell extract, preserving a reaction buffer with a second non-reducing sugar alcohol to provide a preserved reaction buffer, and preserving an energy source, so that the cell extract, the reaction buffer, and the energy source are preserved separately.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: April 10, 2018
    Assignee: The Johns Hopkins University
    Inventor: David K. Karig
  • Patent number: 9910040
    Abstract: A molecular net formed as a branched pseudorandom copolymer including two broad classes of subunits: capture agents and linking agents. The subunits self-assemble to form a structure capable of binding to predetermined targets. The binding can then be detected.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: March 6, 2018
    Assignee: Sevident, Inc.
    Inventors: Emily A. Stein, Michael A. Evans
  • Patent number: 9901648
    Abstract: Compositions and methods for stabilizing biomolecules are disclosed. Specifically, the compositions include novel homopolymers or copolymers containing trehalose side chains conjugated to biomolecules. When such homopolymers or copolymers are placed in close proximity to biomolecules, such as proteins, the homopolymers or copolymers protect and/or stabilize the biomolecule. The compositions and methods may be suitable for use in various industries such as healthcare (pharmaceuticals), molecular biology, biofuels, paper, personal care, detergent, photographic, rubber, brewing, dairy and food processing industries.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 27, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Heather D. Maynard, Rock J. Mancini, Juneyoung Lee, En-Wei Lin
  • Patent number: 9890245
    Abstract: Disclosed are multi-arm polyethylene glycol derivatives having structure of formula I or formula VI. Compared with straight chain polyethylene glycol, multi-arm polyethylene glycol has a plurality of terminal groups, thus has a plurality of introducing points of functional groups and can support a plurality of reactive terminal groups, thereby enabling multi-arm polyethylene glycol to have more flexibility and wider range of application.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: February 13, 2018
    Assignee: JENKEM TECHNOLOGY CO., LTD. (TIANJIN)
    Inventors: Junye Li, Meina Lin, Xiaomeng Chen
  • Patent number: 9878048
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: January 30, 2018
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Patent number: 9880168
    Abstract: The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumor necrosis factor alpha (TNF? or TNF) treatment to asses the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNF? treatment.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Zoltán Konthur, Hans Lehrach, Karl Skriner
  • Patent number: 9869681
    Abstract: The present invention relates to the use of a compound, suitable for modulating the interaction between first and second partner proteins, or between homologues, mutants, or fragments of said proteins, said first and second proteins being SASPase and filaggrin-2, or FLG2, as an active agent for treating and/or preventing aesthetic defects in the skin, and/or in the appendages thereof, linked to an imbalance in the differentiation and/or proliferation of the cells of the epidermis.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: January 16, 2018
    Assignee: L'OREAL
    Inventors: Dominique Bernard, Agnes Thomas-Collignon, Roger Rozot, Benoit Muller
  • Patent number: 9861710
    Abstract: A system is provided which includes the composite nanoparticles configured to bind with a target analyte, the composite nanoparticles including a polymer matrix; nanoparticles at least one type; reporter labels at least one type; and targeting entities at least one type, wherein the nanoparticles at least one type, the reporter labels at least one type and the targeting entities at least one type are encapsulated in the polymer matrix; a body-mountable device mounted on an external surface of a living body and configured to detect a target analyte binding response signal transmitted through the external surface, wherein the target analyte binding response signal is related to binding of the composite nanoparticles with one or more target analytes; and a processor configured to non-invasively detect the one or more target analytes based on the target analyte response signal. Composite nanoparticles and methods for use and for making are also provided.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: January 9, 2018
    Assignee: Verily Life Sciences LLC
    Inventors: Timothy Tordella Ruckh, Kimberly Kam, Jerrod Joseph Schwartz, Vasiliki Demas, Andrew Peter Homyk
  • Patent number: 9849145
    Abstract: Provided is a pharmaceutical composition useful for prevention and/or treatment of diseases caused by bacteria, wherein the pharmaceutical composition comprising a honeysuckle extract containing iridoid compounds and an antibiotic. Also provided is a pharmaceutical kit comprising the honeysuckle extract containing the iridoid compounds and the antibiotics which are separately placed. The honeysuckle extract is used in combination with the antibiotics, the responsiveness of multi-drug resistant bacteria to antibiotics is improved, a clinical application prospect is presented, especially the current status of the refractory bacterial infection diseases caused by the pathogenic bacteria resistant to the antibiotics can be improved. Also provided is a use of the pharmaceutical composition and pharmaceutical kit in the preparation of drugs for prevention and/or treatment a diseases caused by bacteria.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: December 26, 2017
    Assignee: Hankang Biochemical & Pharmaceutical Co., Ltd
    Inventors: Tiejun Zhang, Jiangong Shi, Hong Meng, Fengnian Han, Xuwei Ma, Zhulan Li
  • Patent number: 9841410
    Abstract: A liquid reagent composition for detecting phenol or phenol derivatives includes a reagent capable of generating a stained product by forming a bond with phenol, an oxidant compound or mixture of oxidant compounds, a basic compound or mixture of basic compounds. The ratio of [stained reagent]:[oxidant compound] is 1:2 to 50:1, having a pH greater than 7. Also disclosed is a kit for the use of the composition and liquid-phase method for analysing a fluid potentially containing phenol or a phenol derivatives.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: December 12, 2017
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Thu-Hoa Tran-Thi, Laurent Mugherli, Ana Borta
  • Patent number: 9827285
    Abstract: Provided herein are compositions, formulations, kits, and methods for improving or modifying cognitive performance in an individual having normal-age related cognitive decline. The composition can include an amount of a blueberry extract, L-carnosine, a green tea extract, vitamin D3, and a grape extract. The composition can be included in a pharmaceutical formulation and be administered to a subject having normal-age related cognitive decline according to a dosing regimen.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: November 28, 2017
    Assignees: University of South Florida, Natura Therapeutics, Inc., The Unites States of America as Represented by the Department of Veterans Affairs Office of General Counsel—PSG IV (024)
    Inventors: Paula C. Bickford, Cyndy Davis Sanberg, Jun Tan, Roland Douglas Shytle, Paul D. Sanberg
  • Patent number: 9814769
    Abstract: Provided herein are compositions and methods for vaccinating against infection with pathogenic Escherichia coli (E. coli). In some embodiments, the compositions may include a vaccine including an immunogenic portion of at least two E. coli proteins described herein.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 14, 2017
    Assignee: QATAR UNIVERSITY
    Inventors: Haitham Tawfiq Ghunaim, Marawan A. Abu Madi, Andrew Potter, Brenda Allan
  • Patent number: 9814764
    Abstract: Among other things, the present invention provides methods and compositions of treating Sanfilippo syndrome type B (Sanfilippo B) by, e.g., intrathecal (IT) administration of a Naglu protein. A suitable Naglu protein can be a recombinant, gene-activated or natural protein. In some embodiments, a suitable Naglu protein is a recombinant Naglu protein. In some embodiments, a recombinant Naglu protein is a fusion protein containing a Naglu domain and a lysosomal targeting moiety. In some embodiments, the lysosomal targeting domain is an IGF-II moiety.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: November 14, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Michael F. Concino, Pericles Calias, Jing Pan, Kevin Holmes, Paolo Martini, Alla Romashko, Muthuraman Meiyappan, Bohong Zhang, Andrea Iskenderian, Dianna Lundberg, Angela Norton, Bettina Strack-Logue, Huang Yan, Mary Alessandrini, Richard Pfeifer
  • Patent number: 9809632
    Abstract: Disclosed herein are chimeric proteins that include one or more double stranded nucleic acid binding domains (dsNABD) and one or more polyHis domains, and compositions that further include a therapeutic double stranded nucleic acid and a targeting ligand bound to the therapeutic double stranded nucleic acid, wherein the dsNABD of the chimeric protein is bound to the therapeutic double stranded nucleic acid, and uses of the compositions to treat disease.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 7, 2017
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: Xiaohu Gao, Hong Yan Liu
  • Patent number: 9790237
    Abstract: Novel processes, and intermediates, for making alkylated arylpiperazine and alkylated arylpiperidine compounds of the general formulas (I) and (VII), respectively wherein, R1 and R2 are individually selected from hydrogen, alkyl, substituted or alkyl; n=0, 1, or 2; Y=NR3R4, OR5, or SR5, where R3 and R4 are individually selected from acyl or sulfonyl, and where R5 is aryl or heteroaryl, or heterocyclic; and Ar is an aryl, heteroaryl, or heterocyclic compound.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: October 17, 2017
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Daniel J. Coughlin, Jeremy C. Wilt, Da-Ming Gou, Steven Collier
  • Patent number: 9777069
    Abstract: Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine at the 3-position of one of the phenyl rings. Antibodies produced from immunogenic EDDP conjugates and labeled EDDP conjugates are employed in assays for determining the presence and/or amount of EDDP in samples suspected of containing EDDP.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 3, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventor: Bhalchandra Lele
  • Patent number: 9751933
    Abstract: Provided is an antibody specifically binding to the CTLD (C-type lectin like domain) of clec14a (C-type lectin domain family 14, member A), a method for preparing the antibody, a composition for suppressing angiogenesis comprising the antibody, a method for suppressing angiogenesis by administering the antibody or the composition, a composition for preventing or treating cancer comprising the antibody, a method for treating cancer by administering the antibody or the composition, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for diagnosing cancer using the composition, a composition for suppressing angiogenesis comprising a material for inhibiting expression of clec14a, a kit for angiogenesis comprising the composition, a method for suppressing angiogenesis or treating cancer using the composition, and the use of the CTLD of clec14a as an epitope for an antibody suppressive of angiogenesis.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: September 5, 2017
    Assignee: SCRIPPS KOREA ANTIBODY INSTITUTE
    Inventors: Suk Mook Lee, Min kyoung Ki, Mee Hyun Jeoung, Jong Rip Choi
  • Patent number: 9733242
    Abstract: Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 15, 2017
    Assignee: Sevident, Inc.
    Inventors: Emily Stein, Bruce Phelps, Robert Place, Dina Uzri
  • Patent number: 9714939
    Abstract: Through special formulations, stable twenty-fold concentrate of single component TMB substrate is produced to minimize the volume and reduce the transportation cost. Reconstitution of the concentrate upon delivery to the distal site can be made with deionized water to yield single component TMB substrate solution for routine immunodiagnostic applications.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: July 25, 2017
    Inventor: Hao Zhang
  • Patent number: 9708412
    Abstract: Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 18, 2017
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Luke Evnin, Jeanmarie Guenot, Vanitha Ramakrishnan, Holger Wesche
  • Patent number: 9645132
    Abstract: The present invention relates to a method for stabilizing fatty acids present in a sample such as bodily fluids. The present invention further relates to a solid medium which is capable of stabilizing fatty acids applied thereto, and a method for preparing same. The present invention further relates to a method for determining the fatty acid composition of a sample.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: May 9, 2017
    Assignee: ADELAIDE RESEARCH & INNOVATION PTY LTD
    Inventors: Robert Gibson, Liu Ge
  • Patent number: 9561247
    Abstract: The present invention provides compositions and methods useful in the treatment of wounds, particularly in reducing or preventing scar formation, particularly hypertrophic scar or keloid formation. The invention thus further provides methods of treatment, including methods useful in hypertrophic scar or keloid revision as well as prophylactic, scar inhibiting methods.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: February 7, 2017
    Assignee: TIF Management, LLC
    Inventors: Tien Nguyen, Kathleen Prudhomme, Ronald Yamamoto, Adam G. Lowe, Andrew Michael Green
  • Patent number: 9549968
    Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: January 24, 2017
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
  • Patent number: 9528100
    Abstract: The present invention relates to novel subtilase variants exhibiting alterations relative to the parent subtilase in one or more properties including: Wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dishwash compositions, including automatic dishwash compositions.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 27, 2016
    Assignee: Novozymes A/S
    Inventors: Tina Sejersgard Fano, Claus Von Der Osten, Malene Kappen Kruger, Mads Norregaard-Madsen